

# Accepted Manuscript

Two-year continuation of intrauterine devices and contraceptive implants in a mixed-payer setting: A retrospective review

Jessica N. Sanders, PhD MSPH, David K. Turok, MD MPH, Lori M. Gawron, MD MPH, Amy Law, PharmD, Lonnie Wen, PhD, Richard Lynen, MD, MBA



PII: S0002-9378(17)30180-1

DOI: [10.1016/j.ajog.2017.02.003](https://doi.org/10.1016/j.ajog.2017.02.003)

Reference: YMOB 11523

To appear in: *American Journal of Obstetrics and Gynecology*

Received Date: 7 October 2016

Revised Date: 13 December 2016

Accepted Date: 1 February 2017

Please cite this article as: Sanders JN, Turok DK, Gawron LM, Law A, Wen L, Lynen R, Two-year continuation of intrauterine devices and contraceptive implants in a mixed-payer setting: A retrospective review, *American Journal of Obstetrics and Gynecology* (2017), doi: 10.1016/j.ajog.2017.02.003.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Title: Two-year continuation of intrauterine devices and contraceptive implants in a mixed-payer setting: A retrospective review**

**Authors:**

1 Jessica N. SANDERS, PhD MSPH, The University of Utah Department of Obstetrics and Gynecology

2. David K. TUROK, MD MPH, The University of Utah Department of Obstetrics and Gynecology

3. Lori M. GAWRON, MD MPH, The University of Utah Department of Obstetrics and Gynecology

4. Amy LAW, PharmD, Bayer HealthCare Pharmaceuticals, USA

5. Lonnie WEN, PhD, Bayer HealthCare Pharmaceuticals, USA

6. Richard LYNEN, MD, MBA Bayer HealthCare Pharmaceuticals, USA

**Study location:** Salt Lake City, UT

Conflict of Interest: The University of Utah Department of Obstetrics and Gynecology Program in Family Planning receives research funding from Bayer, Teva, Merck, Bioceptive, and Medicines 360. J.S. and has no conflict of interest to report. L.G. has received honorarium from Evofem. D.K.T. serves on advisory boards for Bayer, Teva, Pharmanest, and Actavis. D.K.T. is a consultant for Bioceptive and a speaker for Allergan and Medicines 360. A.L., L.W., and R.L. are employed by Bayer Healthcare Pharmaceuticals and own stock in the company. AL functions as Bayer's deputy director of the health economics and outcomes research (HEOR) and oversees study conduct, L.W. functions as the deputy director of US HEOR fieldwork, and RL is the study medical expert. A.L., L.W., and R.L. contributed, reviewed and commented on study methodology, analysis approach, study findings, and writing of the manuscript. These individuals were not directly involved with the data collection and analysis.

Funding Source: This study was funded in part by Bayer Healthcare (Whippany, NJ, USA).

Presentation Information: Findings were presented as an abstract and poster at the 28<sup>th</sup> annual Academy of Managed Care Pharmacy (AMCP) San Francisco, CA April 20-22 2016.

Corresponding Author: Jessica N. Sanders; Address: University of Utah Department of Obstetrics and Gynecology, 30 N. 1900 E. Room 2B200, Salt Lake City, UT, 84132; Email: Jessica.sanders@utah.edu Phone: (801) 213-2995 (office); Fax: (801) 585-5146

**Word count:**

Abstract: 296 Main texts: 2491

**Print Version:** Table 1

Download English Version:

<https://daneshyari.com/en/article/5676303>

Download Persian Version:

<https://daneshyari.com/article/5676303>

[Daneshyari.com](https://daneshyari.com)